Document is current
Any future updates will be listed below
-
Authors
Segersvärd, Heli
Sandholm, Niina
Harjutsalo, Valma
Tikkanen, Heidi
Kosonen, Riikka
Laine, Mika
Tikkanen, Ilkka
Groop, Per-Henrik
Lakkisto, Päivi
,
-
Funding
Funding for this research was provided by:
University of Helsinki
- License Information
-
More Information
Article History
Received: 16 June 2025
Accepted: 4 August 2025
First Online: 18 August 2025
Declarations
:
: The study protocol was approved by the Ethics Committee of the HUS Helsinki University Hospital (491/E5/2006, 238/13/03/00/2015, and HUS/3313/2018). The study was conducted in accordance with the Declaration of Helsinki. Before participation, all participants provided informed consent.
: Not applicable.
: P–H.G. has received investigator-initiated research grants from Eli Lilly and Roche, is an advisory board member for AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Cebix, Eli Lilly, Janssen, Medscape, Merck Sharp & Dohme, Mundipharma, Nestlé, Novartis, Novo Nordisk and Sanofi; and has received lecture fees from Astellas, AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Merck Sharp & Dohme, Medscape, Novartis, Novo Nordisk, PeerVoice, Sanofi, and Sciarc. The remaining authors declare that they have no competing interests.
